Medicine and Dentistry
Adverse Event
13%
Albumin
13%
Alpha-Fetoprotein
8%
Arterial Embolization
19%
Bilirubin
10%
Cancer
11%
Cancer Staging
5%
Child-Pugh Score
7%
Clinical Trial
5%
Cryoablation
9%
Disease Exacerbation
5%
Diseases
21%
Doxorubicin
7%
Embolization
25%
Ferumoxytol
6%
Hazard Ratio
9%
Hepatic Portal Vein
12%
Hepatocellular Carcinoma
100%
Infection
6%
International Prostate Symptom Score
5%
Interventional Radiology
8%
Intraarterial Drug Administration
9%
Lipiodol
7%
Liver Cancer
23%
Liver Transplantation
10%
Liver Tumor
13%
Lobectomy
8%
Lower Urinary Tract Symptom
16%
Magnetic Resonance Imaging
19%
Metastatic Carcinoma
9%
Microsphere
14%
Minimally Invasive Procedure
5%
Multivariate Analysis
6%
Neoplasm
37%
Oncology
8%
Overall Survival
29%
Portal Vein Thrombosis
13%
Prostate Hypertrophy
17%
Pulmonary Shunt
11%
Quality of Life
11%
Radioembolization
83%
Recurrent Disease
11%
Scoring System
8%
Segmentectomy
9%
Survival Analysis
5%
Systematic Review
11%
Transcatheter Arterial Chemoembolization
28%
Transjugular Intrahepatic Portosystemic Shunt
5%
Tumor Model
8%
Yttrium 90
67%
Keyphrases
Adverse Events
10%
Albumin
7%
Albumin-bilirubin Grade
8%
Alpha-fetoprotein
9%
Barcelona Clinic Liver Cancer
21%
Benign Prostatic Hyperplasia
16%
Chemoembolization
9%
Child-Pugh Class
6%
Confidence Interval
16%
Conventional Transarterial Chemoembolization (cTACE)
10%
Doxorubicin
8%
Embolization
9%
European Associations
7%
Future Liver Remnant
8%
Hazard Ratio
8%
Hepatocellular Carcinoma
82%
Hepatocellular Carcinoma Patients
12%
Image-guided
11%
Imaging Findings
7%
Interventional Oncology
7%
Interventional Radiology
8%
Liver
11%
Liver Transplantation
12%
Locoregional Therapy
13%
Lower Urinary Tract Symptoms
20%
Lung Shunt Fraction
11%
Magnetic Resonance Imaging
8%
Major Complications
8%
Median Overall Survival
9%
Nanoparticle Uptake
7%
Overall Survival
21%
Patient Cohort
16%
Portal Vein
7%
Portal Vein Embolization
7%
Portal Vein Thrombosis
13%
Prostate Gland
7%
Prostatic Artery Embolization
19%
Radiation Lobectomy
7%
Radiation Segmentectomy
8%
Radioembolization
55%
Scoring System
8%
Surgical Resection
8%
Therapeutic Nanoparticles
7%
Time to Progression
8%
Transarterial Chemoembolization
10%
Transarterial Radioembolization
12%
Transcatheter Arterial Chemoembolization
7%
Tumor
14%
Yttrium-90
21%
Yttrium-90 Radioembolization
36%